UK Standards for Microbiology Investigations

Investigation of Cerebrospinal Fluid
Acknowledgments

UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see https://www.gov.uk/government/groups/standards-for-microbiology-investigations-steering-committee).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the Medical Editors for editing the medical content.

For further information please contact us at:

Standards Unit
Microbiology Services
Public Health England
61 Colindale Avenue
London NW9 5EQ
E-mail: standards@phe.gov.uk

Website: https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories

UK Standards for Microbiology Investigations are produced in association with:
## Amendment Table

Each SMI method has an individual record of amendments. The current amendments are listed on this page. The amendment history is available from standards@phe.gov.uk.

New or revised documents should be controlled within the laboratory in accordance with the local quality management system.

<table>
<thead>
<tr>
<th>Amendment No/Date.</th>
<th>10/31.05.17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issue no. discarded.</td>
<td>6</td>
</tr>
<tr>
<td>Insert Issue no.</td>
<td>6.1</td>
</tr>
<tr>
<td><strong>Section(s) involved</strong></td>
<td><strong>Amendment</strong></td>
</tr>
<tr>
<td>Diagnosis of meningitis.</td>
<td>Table referring to normal values of CSF has been updated to include a wider population: neonates, infants and elderly.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amendment No/Date.</th>
<th>9/24.02.15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issue no. discarded.</td>
<td>5.2</td>
</tr>
<tr>
<td>Insert Issue no.</td>
<td>6</td>
</tr>
<tr>
<td><strong>Section(s) involved</strong></td>
<td><strong>Amendment</strong></td>
</tr>
<tr>
<td>Whole document.</td>
<td>Hyperlinks updated to gov.uk.</td>
</tr>
<tr>
<td>Page 2.</td>
<td>Updated logos added.</td>
</tr>
<tr>
<td>Scope.</td>
<td>Cross reference to G 4 inserted.</td>
</tr>
<tr>
<td>Introduction.</td>
<td>Restructured so that organisms causing meningitis are at the beginning followed by clinical presentations. Normal CSF values table amended to include the ages and the supporting text underneath has been strengthened.</td>
</tr>
<tr>
<td>2.3 Adequate quantity and appropriate number of specimens.</td>
<td>Section clarified to describe how many and what kind of samples should be taken.</td>
</tr>
<tr>
<td>4.3.1 Culture Media.</td>
<td>Slopes added for long term culture of fungi. Culture recommendations for anaerobes have been strengthened.</td>
</tr>
<tr>
<td>4.5.2 Specimen Processing.</td>
<td>The use of 16S PCR and MALDI TOF inserted.</td>
</tr>
<tr>
<td>5.1 Microscopy reporting time.</td>
<td>Guidelines for reporting of cell counts have been given.</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>References.</td>
<td>References reviewed and updated.</td>
</tr>
</tbody>
</table>
UK SMI#: Scope and Purpose

Users of SMIs

Primarily, SMIs are intended as a general resource for practising professionals operating in the field of laboratory medicine and infection specialties in the UK. SMIs also provide clinicians with information about the available test repertoire and the standard of laboratory services they should expect for the investigation of infection in their patients, as well as providing information that aids the electronic ordering of appropriate tests. The documents also provide commissioners of healthcare services with the appropriateness and standard of microbiology investigations they should be seeking as part of the clinical and public health care package for their population.

Background to SMIs

SMIs comprise a collection of recommended algorithms and procedures covering all stages of the investigative process in microbiology from the pre-analytical (clinical syndrome) stage to the analytical (laboratory testing) and post analytical (result interpretation and reporting) stages. Syndromic algorithms are supported by more detailed documents containing advice on the investigation of specific diseases and infections. Guidance notes cover the clinical background, differential diagnosis, and appropriate investigation of particular clinical conditions. Quality guidance notes describe laboratory processes which underpin quality, for example assay validation.

Standardisation of the diagnostic process through the application of SMIs helps to assure the equivalence of investigation strategies in different laboratories across the UK and is essential for public health surveillance, research and development activities.

Equal Partnership Working

SMIs are developed in equal partnership with PHE, NHS, Royal College of Pathologists and professional societies. The list of participating societies may be found at https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories. Inclusion of a logo in an SMI indicates participation of the society in equal partnership and support for the objectives and process of preparing SMIs. Nominees of professional societies are members of the Steering Committee and Working Groups which develop SMIs. The views of nominees cannot be rigorously representative of the members of their nominating organisations nor the corporate views of their organisations. Nominees act as a conduit for two way reporting and dialogue. Representative views are sought through the consultation process. SMIs are developed, reviewed and updated through a wide consultation process.

Quality Assurance

NICE has accredited the process used by the SMI Working Groups to produce SMIs. The accreditation is applicable to all guidance produced since October 2009. The process for the development of SMIs is certified to ISO 9001:2008. SMIs represent a good standard of practice to which all clinical and public health microbiology

---

Microbiology is used as a generic term to include the two GMC-recognised specialties of Medical Microbiology (which includes Bacteriology, Mycology and Parasitology) and Medical Virology.
laboratories in the UK are expected to work. SMIIs are NICE accredited and represent neither minimum standards of practice nor the highest level of complex laboratory investigation possible. In using SMIIs, laboratories should take account of local requirements and undertake additional investigations where appropriate. SMIIs help laboratories to meet accreditation requirements by promoting high quality practices which are auditable. SMIIs also provide a reference point for method development. The performance of SMIIs depends on competent staff and appropriate quality reagents and equipment. Laboratories should ensure that all commercial and in-house tests have been validated and shown to be fit for purpose. Laboratories should participate in external quality assessment schemes and undertake relevant internal quality control procedures.

**Patient and Public Involvement**

The SMI Working Groups are committed to patient and public involvement in the development of SMIIs. By involving the public, health professionals, scientists and voluntary organisations the resulting SMI will be robust and meet the needs of the user. An opportunity is given to members of the public to contribute to consultations through our open access website.

**Information Governance and Equality**

PHE is a Caldicott compliant organisation. It seeks to take every possible precaution to prevent unauthorised disclosure of patient details and to ensure that patient-related records are kept under secure conditions. The development of SMIIs are subject to PHE Equality objectives [https://www.gov.uk/government/organisations/public-health-england/about/equality-and-diversity](https://www.gov.uk/government/organisations/public-health-england/about/equality-and-diversity).

The SMI Working Groups are committed to achieving the equality objectives by effective consultation with members of the public, partners, stakeholders and specialist interest groups.

**Legal Statement**

Whilst every care has been taken in the preparation of SMIIs, PHE and any supporting organisation, shall, to the greatest extent possible under any applicable law, exclude liability for all losses, costs, claims, damages or expenses arising out of or connected with the use of an SMI or any information contained therein. If alterations are made to an SMI, it must be made clear where and by whom such changes have been made.

The evidence base and microbial taxonomy for the SMI is as complete as possible at the time of issue. Any omissions and new material will be considered at the next review. These standards can only be superseded by revisions of the standard, legislative action, or by NICE accredited guidance.

SMIIs are Crown copyright which should be acknowledged where appropriate.

**Suggested Citation for this Document**

**Scope of Document**

**Type of Specimen**
Cerebrospinal fluid

**Scope**

This SMI describes the examination of cerebrospinal fluid (CSF) for the detection and recovery of the causative bacterial or fungal organisms of meningitis. Viruses and other causes of meningitis are mentioned only briefly. For more information on viral meningitis refer to **G 4 – Investigation of Viral Encephalitis and Meningitis** and **V 43 – Investigation of Viral Encephalitis**.

This SMI should be used in conjunction with other SMIs.

**Introduction**

Meningitis is defined as inflammation of the meninges. This process may be acute or chronic and infective or non-infective. Many infective agents have been shown to cause meningitis, including viruses, bacteria, fungi and parasites.

**Organisms Causing Meningitis**

Species isolated tend to be characteristically, but not exclusively, associated with the age or predisposing status of the patient\(^1,2\).

From neonates and babies up to 2 months of age: Lancefield group B streptococci, *Escherichia coli*, *Listeria monocytogenes*, herpes simplex virus and *Neisseria meningitidis*. Premature neonates requiring intensive care are at risk of *Candida* species meningitis as a result of candidaemia.

From children older than two months to young adults: *N. meningitidis*, *Streptococcus pneumoniae*, viruses (in particular enteroviruses) and *Haemophilus influenzae* type b. The incidence of *H. influenzae* type b meningitis in the UK has been greatly reduced by routine Hib immunisation\(^2\).

From adults: *S. pneumoniae*, *N. meningitidis*, viruses and occasionally non-group b *H. influenzae*. Patients older than 60 years without other predisposing factors may develop *Listeria monocytogenes* infection.

Fungi such as *Histoplasma capsulatum*, *Cryptococcus* species and *Coccidioides immitis* may infect the meninges in disseminated infection\(^3\).

Spirochetes such as *Treponema pallidum*, *Borrelia* and *Leptospira* species may cause meningitis as part of a generalised infection.

Parasites (such as the amoebae *Acanthamoeba* species and *Naegleria species*) occasionally cause meningitis. *Naegleria fowleri* invades the meninges via the cribriform plate in freshwater swimmers who inhale small quantities of water, giving rise to florid meningoencephalitis with a high fatality rate.

The nematode *Angiostrongylus cantonensis*, which has a distribution mainly in South East Asia and has also reported from the Dominican Republic, may cause eosinophilic meningitis in infected persons\(^4\).
Many other organisms have been documented to cause meningitis and cannot all be covered in this document.

**Acute Bacterial Meningitis**

Acute bacterial meningitis is a medical emergency. Symptoms and signs of meningitis may evolve over a few days or have a rapid onset and fulminant course over a few hours. The clinical picture may be dominated by accompanying sepsicaemia, as with meningococcal infection. Untreated, mortality is high. It is imperative that any specimen taken from a patient is processed as rapidly as possible, to optimise clinical management. Typically, the CSF becomes infiltrated with neutrophil leucocytes and has raised protein and reduced glucose concentrations.

A number of conditions predispose individual patients to develop meningitis. Abnormal post-surgical and traumatic communications between the subarachnoid space and colonised sites (e.g., the nose and paranasal sinuses following basilar skull fracture), presence of CSF shunts, presence of cochlear implants, meningomyelocele and other congenital malformations, infections of contiguous sites (e.g., the middle ear cavity or paranasal sinuses) and tumours in close proximity to the central nervous system are some examples. As well as direct spread, meningeal infection may occur as a result of blood-borne seeding from a distant site. Patients with immune dysfunction (such as complement deficiency syndromes, or hypogammaglobulinaemia) or who are receiving immunosuppressive treatment are at increased risk of meningitis.

Mixed infections are rare but can occur with certain predisposing conditions. They are associated with trauma, tumours or infections such as acute paranasal sinusitis that may extend directly to the meninges. Mixed infections may also arise by direct entry of organisms via fistulae or as a result of a ruptured brain abscess.

**Viral Meningitis**

Viral meningitis is usually benign and complications are rare. The course is often subacute, evolving over two or three days. The major cause is enteroviral infection, especially in the summer and autumn months. Lymphocyte predominance in the CSF is typical but it must be remembered that early in the course of the disease, both neutrophils and lymphocytes (sometimes with neutrophil predominance) may be seen. CSF glucose concentration is usually normal and protein concentration normal or slightly raised. For more information refer to **G 4 – Investigation of Viral Encephalitis and Meningitis**.

**Chronic Meningitis**

Chronic meningitis is said to be present when signs and symptoms of meningeal inflammation (including abnormalities in the CSF) have been present for a month or more.

A principal infective cause of this condition is tuberculous meningitis. In an established case the CSF may be infiltrated with lymphocytic cells. Tuberculous meningitis has insidious and protean clinical manifestations. It is generally rare in the UK but the diagnosis should be considered in patients from areas of high TB prevalence and in high risk groups. For further information see **B 40 - Investigation of Specimens for Mycobacterium species**.
Other Types of Meningitis

Sarcoid meningitis is very rare and produces a raised protein concentration and leucocyte count together with lesions on the meninges seen on magnetic resonance imaging. Sarcoidosis is a multi-organ disease where the cause is unknown, although it has been postulated that it may be a result of the exposure of genetically susceptible individuals to infectious agents.

Carcinogenous meningitis arises from metastasis from a primary site to the meninges and diagnosis usually rests on the presence of cranial nerve lesion symptoms eg deafness, and by use of magnetic resonance imaging and cytological examination of the CSF for signet cells. It is also important to distinguish between true infection and the result of the malignancy because the two may co-exist.

Special Risk Groups

Patients who are immunosuppressed are additionally susceptible to meningitis caused by organisms such as *Listeria monocytogenes*, *Cryptococcus neoformans*, *Norcardia* and *Toxoplasma gondii*.

Patients with intracranial prosthetic material such as CSF shunts (see B 22 - Investigation of Cerebrospinal Fluid Shunts) are susceptible to infection caused by *Staphylococcus aureus*, coagulase-negative staphylococci, *Corynebacterium* species, *Propionibacterium* species, *Candida* species and *Enterobacteriaceae*.

Diagnosis of Meningitis

Diagnosis of meningitis is best established by laboratory examination of the CSF. This is usually obtained by lumbar puncture, although ventricular, cisternal or fontanelle taps may also be used. Lumbar puncture may cause cerebral herniation, therefore in patients where there is a risk of increased intracranial pressure CT scanning is advised prior to the procedure. In some cases the patient is too unstable or has a bleeding diathesis as a result of sepsis syndrome and cannot undergo immediate lumbar puncture. Blood cultures and pharyngeal swabs may be useful in addition to CSF examination in the diagnosis of meningococcal meningitis and serology may allow retrospective diagnosis on acute and convalescent sera.

In patients for whom lumbar puncture is contraindicated, every effort must be made to establish a microbiological diagnosis by other means. This is desirable both for epidemiological purposes and for the appropriate management of contacts of cases.

The diagnosis of meningitis from the examination of CSF includes the following:

- Complete cell count
- Differential leucocyte count
- Examination of Gram stained smear
- Culture
- Determination of glucose and protein concentrations (usually performed by clinical biochemistry departments)
- PCR where appropriate
- Antigen testing
Therapy should not be delayed pending CSF microscopy or culture. It is important to initiate effective antimicrobial therapy quickly, and this may commence before the examination of the CSF. Further early management decisions therefore, should be based on the immediate examination of the sample by cell count and Gram stain. Examination of the deposit by cytocentrifugation (eg Cytospin) is the most accurate method of cell differentiation but may not be routinely available.

PCR tests are available as a diagnostic procedure for viruses (for more information refer to G 4 – Investigation of Viral Encephalitis and Meningitis) and some other microorganisms although these techniques remain expensive and show differences in sensitivity and specificity between primer sets and laboratory set ups. A broad-range bacterial PCR primer set has been established and this detects organisms that are found less frequently or that are unknown causative agents for bacterial meningitis. It may be particularly useful in situations where culture is negative because of chemotherapy, and serology may also be helpful retrospectively in patients who survive. However accuracy of the 16S rDNA PCR approach differs depending on the sample, the microorganisms involved, the expected bacterial load and the presence of bacterial DNA other than that from the pathogen implied in the infectious disease.

The bacteria commonly causing meningitis carry specific polysaccharide surface antigens that can be detected by Latex Agglutination Test (LAT). LATs are expensive, reliability is disputed and sensitivity is poor. LAT should not be used on CSF unless the cell count is abnormal, Gram stained film is negative and CSF and blood cultures remain negative after 48hr. The clinician should be informed that, although a positive LAT indicates the presence of an infectious agent, a negative result is not definitive. The routine use of LAT is not recommended in this SMI.

CSF cryptococcal antigen testing should be carried out in all cases of suspected cryptococcal meningitis, and all cases of meningitis in immunocompromised patients in which there is an elevated CSF white cell count and no alternative diagnosis has been made. In these cases serum should also be tested for cryptococcal antigen (CRAG).

<table>
<thead>
<tr>
<th>Normal CSF values</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Leucocytes</th>
<th>Neonates</th>
<th>less 28 days</th>
<th>0-30 cells x 10⁶/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants</td>
<td>1 to 12 months</td>
<td>0-15 cells x 10⁶/L</td>
<td></td>
</tr>
<tr>
<td>Children/Adults</td>
<td>1 year +</td>
<td>0-5 cells x 10⁶/L</td>
<td></td>
</tr>
</tbody>
</table>

| Erythrocytes | No RBCs should be present in normal CSF |

<table>
<thead>
<tr>
<th>Glucose</th>
<th>Neonates</th>
<th>less 28 days</th>
<th>1.94-5.55 mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants</td>
<td>29 to 58 days</td>
<td>1.55-5.55 mmol/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2-12 months</td>
<td>1.94-5.0 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Children/Adults</td>
<td>1 year +</td>
<td>2.22-4.44 mmol/L</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Proteins</th>
<th>Neonates</th>
<th>less 28 days</th>
<th>0.65-1.5 g/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants</td>
<td>29-56 days</td>
<td>0.5-0.9 g/L</td>
<td></td>
</tr>
<tr>
<td>Children</td>
<td>2 months to 18 years</td>
<td>0.05-0.35 g/L</td>
<td></td>
</tr>
<tr>
<td>Adults</td>
<td>over 60</td>
<td>0.15-0.6 g/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18 to 60</td>
<td>0.15-0.45 g/L</td>
<td></td>
</tr>
</tbody>
</table>
These values represent the approximate upper and lower limits of normality and are for guidance only.

**Abnormalities associated with bacterial meningitis**

- Reduced glucose concentration: <60% blood glucose (CSF: serum ratio <0.6)
- Elevated protein concentration
- Raised white blood cell (WBC) count: $10^1 - 10^4$ predominantly polymorphs
- Elevated intracranial pressure

The presence of RBCs in CSF can result from an intra-cerebral or sub-arachnoid haemorrhage or from a traumatic lumbar puncture (LP) in which peripheral blood contaminates the CSF. The presence of this contaminating blood may make interpretation of the CSF analysis more difficult but rarely obscures CSF abnormalities associated with bacterial meningitis.

Sequential samples 1 and 3, from one lumbar puncture, are examined. Uniform bloodstaining of all samples suggests previous haemorrhage into the sub-arachnoid space, whereas reducing counts in sequentially obtained samples suggest bleeding induced by the tap procedure.

A WBC:RBC ratio of 1:500 to 1:1000 is generally regarded as not indicative of infection. CSF obtained more than 12hr post intra-cranial haemorrhage may show raised WBC counts of up to $500 \times 10^6$/L as a result of an inflammatory response.

Although patients with untreated acute bacterial meningitis usually have high CSF polymorph counts, the CSF polymorph:lymphocyte ratio is unreliable as a pointer to the cause of meningitis. This is particularly so in neonates or when total leucocyte counts are less than $1000 \times 10^6$/L. Viral meningitis is classically described as being associated with a lymphocytic CSF but neutrophils may predominate, especially early in the illness. Tuberculosis meningitis may also be associated with a neutrophil rather than a lymphocytic infiltrate early in the infection. Neutropenic patients may not produce reliable or characteristic polymorph or neutrophil responses in the CSF.

Occasionally examination of a wet preparation or performance of an India ink preparation will be indicated for the detection of amoebae and C. neoformans respectively. The latter is essential if cryptococcal infection is suspected in a patient who is immunocompromised, this should be confirmed by latex agglutination.

**Xanthochromia**

Xanthochromia is yellow colouration of the supernatant of centrifuged CSF. It can result from the metabolism of products of RBC breakdown, increased CSF protein concentration, or bilirubin staining. RBC breakdown in CSF commences approximately 1-2 hours post haemorrhage. The supernatant may initially be pink in colour due to the presence of oxyhaemoglobin. After 24 hours, the supernatant begins to show increasing xanthochromia caused by the degradation of oxyhaemoglobin to bilirubin. This usually peaks at 36-48 hours.

In sub-arachnoid haemorrhage xanthochromia is associated with a ten-fold increase in protein to ≥1.5g/L which peaks at 8-10 days post onset and then declines. In a fresh, traumatic lumbar puncture the CSF supernatant is usually clear and colourless, although other factors may contribute to its appearance.
Visual determination is unreliable. Xanthochromia should be determined by examination of the supernatant of centrifuged CSF by spectrophotometry to seek macroscopically invisible haematin or bilirubin, which, if present, will confirm pre-tap intracranial haemorrhage²⁹.

**Technical Information/Limitations**

**Limitations of UK SMIs**

The recommendations made in UK SMIs are based on evidence (eg sensitivity and specificity) where available, expert opinion and pragmatism, with consideration also being given to available resources. Laboratories should take account of local requirements and undertake additional investigations where appropriate. Prior to use, laboratories should ensure that all commercial and in-house tests have been validated and are fit for purpose.

**Selective Media in Screening Procedures**

Selective media which does not support the growth of all circulating strains of organisms may be recommended based on the evidence available. A balance therefore must be sought between available evidence, and available resources required if more than one media plate is used.

**Specimen Containers³⁰,³¹**

SMIs use the term “CE marked leak proof container” to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU in vitro Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: “The design must allow easy handling and, where necessary, reduce as far as possible contamination of, and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes”.


1 Safety Considerations

1.1 Specimen Collection, Transport and Storage

Use aseptic technique.

Collect specimens in appropriate CE marked leak proof containers and transport in sealed plastic bags.

Compliance with postal, transport and storage regulations is essential.

1.2 Specimen Processing

The processing of most diagnostic work can be carried out at Containment Level 2 unless infection with a) *N. meningitidis*, b) a Hazard group 3 organism or c) TSE is suspected.

a) *N. meningitidis* causes severe and sometimes fatal disease. Laboratory acquired infections have been reported. The organism infects primarily by the respiratory route. An effective vaccine is available for some meningococcal groups.

*N. meningitidis* is a Hazard group 2 organism and the processing of diagnostic samples can be carried out at Containment Level 2.

Due to the severity of the disease and the risks associated with generating aerosols of the organism, any manipulation of suspected isolates of *N. meningitidis* should always be undertaken in a microbiological safety cabinet until *N. meningitidis* has been ruled out (as must any laboratory procedure giving rise to infectious aerosols).

b) Where Hazard Group 3 *Mycobacterium* species are suspected, all specimens must be processed in a microbiological safety cabinet under full containment level 3 conditions.

c) Refer to [https://www.gov.uk/government/groups/advisory-committee-on-dangerous-pathogens](https://www.gov.uk/government/groups/advisory-committee-on-dangerous-pathogens) for guidance on TSE agents. Laboratory policies that take into account the local risk assessments may dictate that the use of a microbiological safety cabinet should be used when dispensing the specimen.

Laboratory procedures that give rise to infectious aerosols must be conducted in a microbiological safety cabinet.

Prior to staining, fix smeared material by placing the slide on an electric hotplate (65-75°C), under the hood, until dry. Then place in a rack or other suitable holder.

**Note:** Heat-fixing may not kill all *Mycobacterium* species. Slides should be handled carefully.

Centrifugation must be carried out in sealed buckets which are subsequently opened in a microbiological safety cabinet.

Specimen containers must also be placed in a suitable holder.

Refer to current guidance on the safe handling of all organisms documented in this SMI.

The above guidance should be supplemented with local COSHH and risk assessments.
2 Specimen Collection

2.1 Type of Specimens

CSF

2.2 Optimal Time and Method of Collection

For safety considerations refer to Section 1.1.

Collect specimens preferably before antimicrobial therapy is started, but this must not be delayed unnecessarily pending lumbar puncture and CSF culture.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

Specialist collection according to local protocols.

2.3 Adequate Quantity and Appropriate Number of Specimens

CSF is normally collected sequentially into three or more separate containers which should be numbered consecutively. Collect specimens in appropriate CE marked leak proof containers and transport specimens in sealed plastic bags.

Collection of an additional sample in a container with fluoride for glucose estimation is also recommended, although such tubes should be filled last because they may contain environmental bacteria which might otherwise contaminate samples for culture.

Common practice is to send the first and last specimens taken for microbiological examination and the second specimen for protein. The fluoride sample should not be sent to Microbiology. Ideally testing should be carried out on the last sample with the first one reserved as a backup.

Ideally a minimum volume of 1mL for each tube 1 and 3 taken for microscopy (in adults). When sample volume is below this it is possible to pool samples.

For Mycobacterium species, at least 10mL where possible.

Note: The larger the volume, the greater the cultural yield particularly in relation to M. tuberculosis investigations.

3 Specimen Transport and Storage

3.1 Optimal Transport and Storage Conditions

For safety considerations refer to Section 1.1.

Time between collection to microscopy and culture should occur within a maximum of 2 hours. Cells disintegrate and a delay may produce a cell count that does not reflect the clinical situation of the patient.

Specimens should be transported and processed as soon as possible.

Do not refrigerate specimen until after microscopy and bacterial culture have been performed. The specimen should then be refrigerated pending further investigation.
4 Specimen Processing/Procedure\textsuperscript{30,31}

4.1 Test Selection

Specimens taken after routine neurological examination (e.g., myelogram, multiple sclerosis) do not require Gram film or culture unless the leucocyte count is raised, or these tests are clinically indicated or specified in local protocols.

Divide specimen, if multiple samples are not taken after performing microscopy and bacterial culture, for appropriate procedures such as protein estimation, culture for *Mycobacterium* species (B 40 - Investigation of Specimens for *Mycobacterium* species), examination for parasites (B 31 - Investigation of Specimens other than Blood for Parasites), screening for cryptococcal antigen or virology as may be appropriate in view of clinical details, tests requested or microscopy results.

**Note:** If there is an insufficient volume of sample for all investigations, these should be prioritised following medical microbiological advice.

Rapid screening for antigens in CSF from cases of bacterial meningitis is not recommended routinely. However, it may be useful for example when deciding if two or more cases of the same type have occurred in a school (to guide mass prophylaxis or vaccination).

PCR is available as a diagnostic procedure for some organisms. An unopened sample, if available, is preferred for PCR.

4.2 Appearance

Describe turbidity and whether a clot is present (which would invalidate the cell count).

In extreme cases of TB meningitis a typical 'spider-web' clot may be present. Although rarely seen, its presence should be noted.

Record if the estimated specimen volume is insufficient for all investigations to be performed and obtain medical microbiological advice about prioritisation if appropriate.

Describe colour of supernatant after centrifugation.

Confirmation of xanthochromia should be performed by spectrophotometry if requested or if clarification of the source of RBCs in the CSF is required\textsuperscript{29}. This is often carried out by clinical biochemistry departments as are protein and glucose determinations.

4.3 Sample Preparation

For safety considerations refer to Section 1.2.

See Microscopy section.

4.4 Microscopy

4.4.1 Standard total cell count

Perform total WBC and RBC counts on the uncentrifuged specimen, preferably the last specimen taken, using a counting chamber.

Cell counts should not be performed on specimens containing a clot (which invalidates the result).
Differential leucocyte count

1. Counting chamber method (recommended for lower WBC counts)
   a) Non- or lightly bloodstained specimens
   Stain the unspun CSF with 0.1% stain solution such as toluidine, methylene or Nile blue. These stain the leucocyte nuclei aiding differentiation of the cells. If the CSF is diluted when adding the stain, remember to take the dilution factor into account when calculating the final cell count.
   Count and record the actual numbers of each leucocyte type. Express the leucocyte count as number of cells per litre.
   b) Heavily bloodstained specimens
   Dilute specimen with WBC diluting fluid and leave for 5 min before loading the counting chamber. This will lyse the RBCs and stain the leucocyte nuclei for differentiation.
   Count and record the actual numbers of each leucocyte type. Taking the dilution factor into account, express as number of cells per litre.

2. Stained method (recommended for very high WBC counts where differentiation in the counting chamber is difficult)
   Prepare a slide from the CSF centrifuged deposit as for the Gram stain, but allow to air dry. Fix in alcohol and stain with a stain suitable for WBC morphology.

   Note 1: Heat fixation distorts cellular morphology.

   Note 2: Count and record the actual numbers of each leucocyte type. Taking the dilution factor into account, express as number of cells per litre.

   Note 3: A cytocentrifugation deposit (eg Cytospin) permits the most accurate cell differentiation. Care should be taken to use a sterile tube if this deposit is to be used for Gram stain examination.

Total red cell count
If haemorrhage is suspected, perform a total RBC count on a minimum of two specimens from the same lumbar puncture to assess uniformity of bloodstaining. Isotonic or phosphate buffered saline should be used for any dilutions required.

Gram stain (refer to TP 39 - Staining Procedures)
Perform Gram stain on all specimens except:
- Clotted specimens (see below)
- Routine neurological specimens unless leucocyte counts are raised
- PM specimens cell counts are unreliable but should be cultured

Centrifuge in a sterile, capped, conical-bottomed container at 1200 xg for 5-10 min.

   Note: If investigation for Mycobacterium species is also requested, the centrifugation time may be increased to 15-20 min at 3000 xg (see B 40 - Investigation of Specimens for Mycobacterium species) and the same deposit used for this as well as routine microscopy and culture.

Transfer all but the last 0.5mL of the supernatant with a sterile pipette to another sterile container for additional testing if required (eg protein, virology).
Resuspend the deposit in the remaining fluid.
Place one drop of centrifuged deposit with a sterile pipette on a clean microscope slide.
Spread this with a sterile loop to make a thin smear for Gram staining.
The sensitivity of the Gram stain may be improved by serial drops being "built up" on the slide after each drop has dried, to maximise the amount examined. Care should be taken to ensure that the smear does not wash off during staining.

**Clotted specimens**
If possible the clot should be broken up with a sterile pipette and a portion used to make a smear for Gram staining.

### 4.4.2 Supplementary

#### Examination for *M. tuberculosis*

The "build up" technique for films as described above is recommended for the examination for *Mycobacterium* species (see [B 40 - Investigation of Specimens for *Mycobacterium* species](#)). If a 'spider-web' clot is present this should be included in the portion of the specimen examined by microscopy and culture.

#### Examination for *C. neoformans*

Mix a drop of the centrifuged deposit with a drop of 50% aqueous India ink or nigrosin on a clean microscope slide and cover with a coverslip (see [TP 39 - Staining Procedures](#)).
Examine for the presence of round or oval yeasts with a clear halo around the cell, indicating the presence of a capsule. The presence of a capsule permits a presumptive identification of *C. neoformans*.

#### Examination for amoebae

Examine both uncentrifuged and centrifuged deposits as wet preparations. Place a drop of specimen on a clean microscope slide, cover with a coverslip and examine for amoebic trophozoites ([B 31 - Investigation of Specimens other than Blood for Parasites](#)).

### 4.5 Culture and Investigation

#### 4.5.1 Pre treatment

**Standard**
Centrifuge specimen (already performed for microscopy - see 4.4).

**Supplementary**

*Mycobacterium* species ([B 40 - Investigation of Specimens for *Mycobacterium* species](#)) and parasites (see [B 31 - Investigation of Specimens other than Blood for Parasites](#)).

#### 4.5.2 Specimen processing

**Standard**
For all CSF
• With a sterile pipette inoculate each agar plate with the centrifuged deposit (see Q 5 - Inoculation of Culture Media for Bacteriology)

• Allow inoculum to dry before spreading to minimise any antibiotic effect which may be present

• Spread inoculum with a sterile loop for the isolation of individual colonies

**Clotted specimens**

Inoculate the clot fragments to each agar plate.

If the specimen contains only a small clot, this should be included in the inoculum applied to the chocolate agar plate. The unclotted portion of the CSF should be cultured in the normal way as described above.

**Supplementary**

If culture negative result from clinically ill patient consider other non-culture methods for diagnosis eg 16S PCR, MALDI TOF, etc.

Broth cultures are not recommended as a significant positive yield is rarely achieved and contamination is frequent, unless dealing with shunt infections where they may add value\textsuperscript{51-53}. 
### 4.5.3 Culture media, conditions and organisms

<table>
<thead>
<tr>
<th>Clinical details/conditions</th>
<th>Specimen</th>
<th>Standard media</th>
<th>Incubation</th>
<th>Cultures read</th>
<th>Target organism(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Temp °C</td>
<td>Atmos</td>
<td>Time</td>
</tr>
<tr>
<td>Meningitis Post neurosurgery</td>
<td>CSF</td>
<td>Chocolate agar</td>
<td>35 - 37</td>
<td>5 - 10% CO₂</td>
<td>40-48hr daily</td>
</tr>
<tr>
<td>Reservoirs Ventriculitis</td>
<td>CSF</td>
<td>Blood agar</td>
<td>35 - 37</td>
<td>5 - 10% CO₂</td>
<td>40-48hr daily</td>
</tr>
</tbody>
</table>

For these situations, add the following:

<table>
<thead>
<tr>
<th>Clinical details/conditions</th>
<th>Specimen</th>
<th>Supplementary media</th>
<th>Incubation</th>
<th>Cultures read</th>
<th>Target organism(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Temp °C</td>
<td>Atmos</td>
<td>Time</td>
</tr>
<tr>
<td>Immunocompromised patients</td>
<td>CSF</td>
<td>Sabouraud plate</td>
<td>35 - 37</td>
<td>air</td>
<td>14d*</td>
</tr>
<tr>
<td>Brain abscess</td>
<td>CSF</td>
<td>Fastidious anaerobe agar</td>
<td>35-37</td>
<td>anaerobic</td>
<td>10d</td>
</tr>
<tr>
<td>Ventriculitis</td>
<td>CSF</td>
<td>Neomycin fastidious anaerobe agar</td>
<td>35-37</td>
<td>anaerobic</td>
<td>10d</td>
</tr>
<tr>
<td>Reservoirs Post neurosurgery Post otitis media with complications</td>
<td>CSF</td>
<td>Neomycin fastidious anaerobe agar</td>
<td>35-37</td>
<td>anaerobic</td>
<td>10d</td>
</tr>
</tbody>
</table>

* If longer culture times are likely to be required a sabouraud slope should be put up in addition to the plate.

Enrichment broths may add value when diagnosing shunt infections (see page 18).

Other organisms for consideration - *Mycobacterium* species and parasites as described in supplementary testing, *T. pallidum* and viruses can be found in relevant SMIs.

### 4.6 Identification

Refer to individual SMIs for organism identification.

#### 4.6.1 Minimum level of identification in the laboratory

<table>
<thead>
<tr>
<th>Anaerobes</th>
</tr>
</thead>
<tbody>
<tr>
<td>species level</td>
</tr>
<tr>
<td>Actinomyces</td>
</tr>
<tr>
<td>species level</td>
</tr>
<tr>
<td>β-haemolytic streptococci</td>
</tr>
<tr>
<td>Lancefield group level</td>
</tr>
</tbody>
</table>
### 4.7 Antimicrobial Susceptibility Testing

Refer to British Society for Antimicrobial Chemotherapy (BSAC) and/or EUCAST guidelines.

### 4.8 Referral for Outbreak Investigations

N/A

### 4.9 Referral to Reference Laboratories

For information on the tests offered, turn around times, transport procedure and the other requirements of the reference laboratory [click here for user manuals and request forms](#).

<table>
<thead>
<tr>
<th>Organism</th>
<th>Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-haemolytic streptococci</td>
<td>Serotyping</td>
</tr>
<tr>
<td><em>S. pneumoniae</em></td>
<td>Serotyping</td>
</tr>
<tr>
<td><em>H. influenzae</em></td>
<td>Serotyping</td>
</tr>
<tr>
<td><em>Listeria</em> species</td>
<td>Serotyping</td>
</tr>
<tr>
<td><em>N. meningitidis</em></td>
<td>Strain characterisation, antimicrobial susceptibility testing</td>
</tr>
<tr>
<td>Fungi</td>
<td>Identification and/or susceptibility testing</td>
</tr>
<tr>
<td><em>Mycobacterium</em> species</td>
<td><a href="#">B 40 - Investigation of Specimens for Mycobacterium species</a></td>
</tr>
</tbody>
</table>

Isolates associated with outbreaks, where epidemiologically indicated and organisms with unusual or unexpected resistance and whenever there is a laboratory or clinical problem or anomaly that requires elucidation should be sent to the appropriate reference laboratory.

CSF, EDTA blood and paired serum samples may be sent to the Meningococcal Reference Unit (MRU) for examination using molecular methods and serological examination if culture is negative and meningococcal infection suspected.

Specimens for molecular testing for other organisms may be sent to appropriate laboratories if clinically indicated.

Organisms with unusual or unexpected resistance, and whenever there is a laboratory or clinical problem, or anomaly that requires elucidation should be sent to the appropriate reference laboratory.

Contact appropriate devolved national reference laboratory for information on the tests available, turn around times, transport procedure and any other requirements for sample submission:

England and Wales

---

**Note:** Any organism considered to be a contaminant may not require identification to species level.

Organisms may be further identified if this is clinically or epidemiologically indicated.
5  Reporting Procedure

5.1  Appearance
Report the appearance of the CSF and the presence of a clot if applicable.

5.2  Microscopy

Cell count
Report numbers of RBCs $\times 10^6$ per litre and
Report numbers of PMNs and lymphocytes $\times 10^6$/L or
Report PMNs and lymphocytes as percentages of the total WBC (which is reported as $\times 10^6$).

In certain cases referral to cytology for identification of mononuclear and other cells may be indicated.

Gram stain
Report on organisms detected and presence or absence of pus cells.

Supplementary
India ink or nigrosin.

Report on encapsulated yeasts detected.


5.2.1  Microscopy reporting time
Results of cell counts and stains should be communicated immediately, within two hours of receiving the specimen and made available on the clinical users’ results viewing system. Where such facilities are not available, written or computer generated reports should follow preliminary/verbal reports within 24 hours.

5.3  Culture
Report the organisms isolated or
Report absence of growth.
Also, report results of supplementary investigations.

Culture reporting time
Clinically urgent culture results to be telephoned or sent electronically when available.
Interim/final written report, 16–72 hours stating, if appropriate, that a further report will be issued.

Molecular testing results (if applicable).

Supplementary investigations: *Mycobacterium* species (B 40 - Investigation of Specimens for *Mycobacterium* species) fungi (B 39 - Investigation of Dermatological Specimens for Superficial Mycoses) and parasites (B 31 - Investigation of Specimens other than Blood for Parasites).

5.4 **Antimicrobial Susceptibility Testing**

Report susceptibilities as clinically indicated. Prudent use of antimicrobials according to local and national protocols is recommended.

6 **Notification to PHE**\(^{54,55}\) or Equivalent in the Devolved Administrations\(^{56-59}\)

The Health Protection (Notification) regulations 2010 require diagnostic laboratories to notify Public Health England (PHE) when they identify the causative agents that are listed in Schedule 2 of the Regulations. Notifications must be provided in writing, on paper or electronically, within seven days. Urgent cases should be notified orally and as soon as possible, recommended within 24 hours. These should be followed up by written notification within seven days.

For the purposes of the Notification Regulations, the recipient of laboratory notifications is the local PHE Health Protection Team. If a case has already been notified by a registered medical practitioner, the diagnostic laboratory is still required to notify the case if they identify any evidence of an infection caused by a notifiable causative agent.

Notification under the Health Protection (Notification) Regulations 2010 does not replace voluntary reporting to PHE. The vast majority of NHS laboratories voluntarily report a wide range of laboratory diagnoses of causative agents to PHE and many PHE Health protection Teams have agreements with local laboratories for urgent reporting of some infections. This should continue.

**Note:** The Health Protection Legislation Guidance (2010) includes reporting of Human Immunodeficiency Virus (HIV) & Sexually Transmitted Infections (STIs), Healthcare Associated Infections (HCAIs) and Creutzfeldt–Jakob disease (CJD) under ‘Notification Duties of Registered Medical Practitioners’: it is not noted under ‘Notification Duties of Diagnostic Laboratories’.


Other arrangements exist in Scotland\(^{56,57}\), Wales\(^{58}\) and Northern Ireland\(^{59}\).

Clinically significant isolates from CSF should be reported to the Regional CIDSC and Local CCDC.

Refer to the following:

Individual SMIs on organism identification.

Health Protection Agency publications:
"Laboratory Reporting to the Health Protection Agency. Guide for diagnostic laboratories”.

Local Memorandum of Understanding.

Current guidelines on CIDSC and COSURV reporting.

In cases of suspected meningococcal disease and contacts the isolation of *N. meningitidis* should be reported to the CCDC immediately.

Report all isolates of the following: *Mycobacterium* species.
Appendix: Investigation of Cerebrospinal Fluid

Prepare specimens

For all specimens

Meningitis
Post neurosurgery
Reservoirs
Ventriculitis
Immunocompromised

Chocolate agar
Incubate at 35-37°C
5 - 10 % CO₂
40 - 48hr
Read daily

Refer to IDs

Additional media

Brain abscesses
Ventriculitis
Reservoirs
Post neurosurgery
Post otitis media with complications

Fastidious anaerobe agar
Incubate at 35-37°C anaerobically
14 d
Read at 40hr and 5 d
Anaerobes
ID 8, 14, 25

Neomycin
Fastidious anaerobe agar

Mixed infection from Gram film

Ventriculitis
Reservoirs
Post otitis media with complications

Immunocompromised patients

Sabouraud agar
Incubate at 35-37°C in air
14d
Read at 40hr

Fungi

Blood agar

Incubate at 35-37°C
5 – 10 % CO₂
40 – 48hr
Read daily

ID 8, 14, 25
References


30. European Parliament. UK Standards for Microbiology Investigations (SMIs) use the term "CE marked leak proof container" to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU in vitro Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: "The design must allow easy handling and, where necessary, reduce as far as possible contamination of, and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes". 1998.


